Build vs partner: when should a UK brand actually build their own pharma infra?

"Should we build it or partner for it?" is the most consequential question a UK telehealth brand answers in its first three years. Get it right and you save eighteen months of regulatory grinding plus several hundred thousand pounds of capex. Get it wrong and you either over-build expensive infrastructure that bleeds margin for years, or you under-build and find yourself trapped inside someone else's roadmap.

This piece walks through the actual decision matrix — layer by layer, threshold by threshold, with worked examples at three different volume bands. It's written for founders sitting at the build-vs-partner crossroads right now.

Disclosure: PExpo is one of the UK platforms a brand might partner with. The framework below is one we apply to ourselves — and to the brands we work with — when this question comes up.

The honest cost of building each layer yourself

A UK telehealth brand has five layers: clinical, intake, dispensing, portal, marketing. (See our launch playbook for the underlying anatomy.) "Building" means owning the people, processes, regulatory posture and operational debt for that layer. "Partnering" means signing a vendor agreement and accepting that someone else owns those things on your behalf.

Here's what building each layer actually costs in 2026:

Clinical. Building means recruiting your own prescriber network — GMC, NMC and GPhC-registered prescribers willing to work asynchronously, under your clinical governance framework. Recruiting a UK prescriber network typically takes six to nine months. You'll need a clinical lead, documented protocols aligned to NICE guidance, audit-trail infrastructure, ongoing CPD support and locum cover. Annual run-rate at meaningful scale: £200k–£500k+ depending on volume.

Intake. Building means designing and engineering your questionnaire flow yourself. The good news: most modern intake builders are commodity. The bad news: clinical pathway design is not commodity. You can buy the engine cheaply; the clinical content costs real money to develop and validate.

Dispensing. Building means standing up a GPhC-registered pharmacy. Standing up a GPhC-registered pharmacy from scratch costs roughly £200k–£500k in year-one fit-out, hiring and licensing, with ongoing operating costs of similar magnitude annually. You need a superintendent pharmacist, premises, SOPs, CD-register procedures, dispensing staff, insurance, software and stock holding. This is by far the most expensive layer to build and the most expensive to get wrong.

Portal. Building means engineering a branded patient-facing surface yourself — sign-up, dashboards, payments, repeat ordering, lifecycle messaging. Most brands underestimate this. Six to twelve months of engineering for a competent v1, plus ongoing maintenance forever after.

Marketing. Always built. There is no "outsource your acquisition" path that works. The only question is which channels and how fast.

The interesting decision isn't whether to build marketing — that's settled. It's where on the clinical-to-portal spectrum your build line should fall.

Capital threshold below which building is never the right call

Most founders intuit that building is hard. They typically miss how brutal the cash flow is during the build period.

A simple model: assume you'd partner today for ~25% margin share with a white-label platform, and assume your gross margin on medication is around 50% (which is roughly average for the categories most brands enter). That means partnering costs you ~12.5% of revenue. To replace that with in-house dispensing, you need to amortise the upfront build cost plus annual operating cost across enough revenue that the per-order in-house cost lands below 12.5%.

At a £150 average order value, you typically need volume of 8,000–10,000 monthly orders before the in-house pharmacy makes financial sense. Most UK brands cross the threshold to start considering in-house pharmacy around 8,000–10,000 monthly orders.

Below that volume? You're paying for fixed regulatory overhead with too few revenue pounds to spread across it. Building beats partnering at low volume only if you have a strategic reason beyond pure economics — and "we should own our infrastructure" is not, on its own, a strategic reason.

Strategic threshold above which building starts to make sense

Pure economics is one threshold. Strategic logic is another, and it kicks in earlier for certain brand profiles.

Build earlier if any of the following apply:

• Category concentration. A brand operating in one or two narrow verticals (e.g. weight management only, or HRT only) has cleaner economics for in-house dispensing because the SKU range is small and demand is predictable.
• Defensive moat thesis. If your investor narrative depends on owning regulated infrastructure as a competitive barrier, you build earlier even if the unit economics don't yet justify it. You're funding the moat, not the operations.
• Vendor failure exposure. If your single dispensing partner has a regulatory finding, a supply disruption or a commercial dispute, your business stops. Some brands choose to own dispensing precisely because they can't accept that single point of failure.
• Acquirer thesis. If you intend to be acquired by a larger pharma or healthcare group, in-house dispensing materially affects your valuation multiple. Most strategic acquirers price brands with their own dispensing higher.

Conversely, stay partnered longer if any of the following apply:

• Multi-category brand. A brand spanning five or more verticals has SKU and operational complexity that scales painfully in-house.
• International ambitions. A brand planning US or EU expansion in the next 24 months should not build UK dispensing first. Build the international layer first; partner UK in the meantime.
• Founder bandwidth. If the founder can't dedicate at least 30% of their attention to building the pharmacy operation for 18 months, the build fails. Full stop.
• Capital scarcity. If the build cost would consume more than 25% of available capital, the brand probably can't afford it without compromising growth investment.

Layer-by-layer build-vs-partner matrix

Here's how the layers typically resolve in 2026:

• Clinical — Build at ~10,000+ monthly orders combined with a strategic moat thesis. Below that, partner.
• Intake — Always build the clinical content (it's your IP). You can use a partner's engine for the conditional logic, but own the questionnaire substance.
• Dispensing — Build at 8,000–10,000 monthly orders with adequate capital and bandwidth. Below that, partner.
• Portal — Always hybrid. Build the patient-facing surface, partner for primitives (payment processing, intake engine, prescriber workflow).
• Marketing — Always build.

The mistake most founders make: trying to build clinical and dispensing simultaneously. The capital required is enormous, the founder bandwidth required is impossible, and the regulatory complexity multiplies non-linearly when both happen at once.

If you have to build one in-house first, it's almost always dispensing. The clinical layer is more portable between partners; the dispensing layer has more lock-in and more margin trapped on the wrong side of the table.

Hybrid model — partner now, transition to build at scale

The most effective approach for most brands is to partner aggressively now and design the partnership with eventual transition in mind.

What that looks like in practice:

1. Sign with a partner who exposes the operational data. You want the dispatch records, the clinical audit trail, the patient retention metrics — all in a form you can export and operate against later.
2. Negotiate offboarding terms up front. What does it look like when you leave? How long do they continue dispensing in-flight orders? Who owns patient communications during the transition? These clauses are easier to get right at signing than at exit. (Our pricing page shows what a transparent commercial structure looks like, which makes offboarding easier to model.)
3. Build your intake content as you go. Even if you're using a partner's intake engine, the clinical questionnaire content is yours. Treat it as a living document you'll port across vendors.
4. Capture the patient relationship in your CRM. Don't let the patient relationship live exclusively in the partner's portal. (Our integrations page shows the kind of data flows that make this work.)
5. Plan the transition window. Most brands that eventually build run new and old infrastructure in parallel for three to six months before fully migrating. Plan that window into your capex when the time comes.

The best build-vs-partner decision isn't "build" or "partner". It's "partner now, prepare to build" — designed at signing, not at exit.

Brands that do this well have the option to flip from partnered to in-house when their volume crosses the threshold. Brands that don't get trapped in their partner's structure even when the economics would favour change.

Worked examples — three brand archetypes at different volumes

Archetype A — new brand, weight-management single category, pre-revenue.

Build: nothing. Partner everything except marketing and intake content. The first six months are about validating CAC, AOV and retention. CQC registration for a new digital clinical service runs 12+ weeks minimum — don't start that clock until you have evidence the category works for you specifically. Once you have 500 active patients, revisit. (See our brand model page for what the layer scope looks like when you partner.)

Archetype B — established brand, 3,000 monthly orders, two categories, profitable.

Build: intake content, portal surface, CRM. Partner: clinical, dispensing. Negotiate better commercial terms with the partner now that you have leverage. Start having the build-vs-partner conversation seriously for dispensing in around twelve months when volume approaches 6,000–8,000.

Archetype C — established brand, 12,000 monthly orders, three categories, well-funded.

Build: dispensing infrastructure, if capital and bandwidth allow. The economic threshold is crossed; the strategic moat thesis is now real. Partner: clinical (still — clinical is portable, dispensing is sticky) and the intake engine (but own the content). Plan the transition over twelve months, run parallel for six, migrate cleanly. Expect £400k–£700k all-in for the in-house pharmacy build, plus a year of operational disruption that no projection captures honestly.

What to do this month

If you're at the start of this question:

• Map your current monthly volume and project the next twelve months realistically.
• Identify which layer is your biggest annual cost as a partnered brand. That's usually the layer to consider building first.
• Talk to your existing partner about transition terms — even if you're not transitioning. Their answer tells you whether they're a long-term partner or a short-term vendor.
• Talk to two brands that built in-house at similar volumes and ask what they wish they'd known.

Build-vs-partner isn't a binary; it's a sequence. The brands that get this right are the ones that build the right layer at the right time — not the ones who try to build everything immediately, and not the ones who never build anything.